NCT00538213View on ClinicalTrials.gov

Evaluation of Safety and Immunogenicity of GSK Bio's Influenza Vaccine GSK576389A After Repeated Vaccination in Elderly Adults

PHASE2CompletedINTERVENTIONAL

Enrollment

133

Participants

Timeline

Start Date

October 15, 2007

Primary Completion Date

November 1, 2007

Study Completion Date

November 28, 2007

Conditions

Influenza

Interventions

BIOLOGICAL

Fluarix™

Single dose, Intramuscular injection

BIOLOGICAL

GSK Bio's Influenza Vaccine GSK576389A

Single dose, Intramuscular injection

Trial Locations (1)

9000

GSK Investigational Site, Ghent

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY